PRINCETON, NJ -- (MARKET WIRE) -- March 08, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that Health Canada’s Therapeutic Products Directorate granted marketing approval to Xolegel™ (ketoconazole, topical gel, 2% w/w) for the treatment of seborrheic dermatitis in immunocompetent adults and children twelve years of age and older. Seborrheic dermatitis is a common, recurring skin inflammation characterized by a red, scaly, itchy rash primarily on the face, scalp, hairline, eyebrows and torso.
